dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gener, Petra |
dc.contributor.author | Fernandes de Rafael, Diana |
dc.contributor.author | Seras Franzoso, Joaquin |
dc.contributor.author | Pérez Martín, Anna |
dc.contributor.author | Alamo Pindado, Luis Angel |
dc.contributor.author | Casas Gimeno, Glória |
dc.contributor.author | Arango Corro, Diego |
dc.contributor.author | Fernández Amurgo, Yolanda |
dc.contributor.author | Abasolo Olaortua, Ibane |
dc.contributor.author | Schwartz Navarro, Simon |
dc.contributor.author | Diaz Riascos, Zamira Vanessa |
dc.date.accessioned | 2020-02-17T13:45:20Z |
dc.date.available | 2020-02-17T13:45:20Z |
dc.date.issued | 2019-07-26 |
dc.identifier.citation | Gener P, Rafael D, Seras-Franzoso J, Perez A, Pindado LA, Casas G, et al. Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells. Cancers. 2019 Jul 26;11(8):1058. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/4645 |
dc.description | Cèl·lules mare canceroses (CSC); Fenotip dinàmic; Transició epitelial a mesenquimal (EMT) |
dc.description.sponsorship | This work was funded by Fondo de Investigaciones Sanitarias (FIS) from ISCIII, Spanish ministry of Economy and Competitiveness, grant PI17/02242 co-financed by The European Regional Development Fund (FEDER); AC15/00092 grant (Target4Cancer project) from Euro-NanoMed II and PENTRI project, financed by Marato TV3, and EvoNano project, funded by European Union's Horizon 2020 FET Open programme under grant agreement. No. 800983. JSR was supported by a post-doctoral grant from Asociacion Espanola Contra el Cancer (AECC). |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;11(8) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Tumors |
dc.subject | Serina-proteases |
dc.subject | Cèl·lules canceroses |
dc.subject.mesh | Neoplastic Stem Cells |
dc.subject.mesh | Receptor-Interacting Protein Serine-Threonine Kinase 2 |
dc.subject.mesh | Breast Neoplasms |
dc.title | Pivotal role of AKT2 during dynamic phenotypic change of breast cancer stem cells |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers11081058 |
dc.subject.decs | células madre neoplásicas |
dc.subject.decs | proteína serina-treonina cinasa 2 de interacción con receptor |
dc.subject.decs | neoplasias de la mama |
dc.relation.publishversion | https://www.mdpi.com/2072-6694/11/8/1058 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Gener P, Seras-Franzoso J, Perez A, Pindado LA, Casas G] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Rafael D] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Arango D] Investigació Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Fernández Y] Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Díaz-Riascos Z] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Abasolo I, Schwartz S] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain |
dc.identifier.pmid | 31357505 |
dc.identifier.wos | 000484438000018 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |